ArticleJournal of materials science. Materials in medicine2026
Hybrid Isoxazole-Hydroxyapatite composites as antimicrobial agents: integrated in silico and in vitro investigation.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, an innovative methodology was implemented to combine an isoxazole derivative (ARZ) with hydroxyapatite (HAp), varying several parameters to obtain three distinct composites (ARZ-Hap-1, ARZ-Hap-2 and ARZ-Hap-3). These composites (ARZ-Hap) were synthesized by a dissolution-recrystallization process, thereby facilitating enhanced interaction between ARZ and HAp. This approach promoted homogeneous dispersion of ARZ within the HAp matrix, consequently enhancing the stability and functionality of the resulting materials. The structural characterization of these composites was determined by FT-IR, XRD, BET, TGA, and NMR (¹³C, ³¹P) methods. Subsequently, the composites were subjected to a rigorous evaluation process to ascertain their antibacterial and antifungal activities. Among them, ARZ-HAp-3 exhibited noticeable antimicrobial activity against E. coli, S. aureus, and B. subtilis, demonstrating a measurable inhibitory effect on bacterial growth. In terms of antifungal activity, this composite demonstrated the best results, particularly against C. albicans and F. oxysporum, with minimal MIC and MFC values comparable to those of fluconazole. These results indicate the potential of the ARZ-HAp-3 composite as a promising bioactive material, demonstrating a combination of structural efficiency and targeted biological activity. The release of ARZ from the composites was monitored by UV-Visible spectroscopy, revealing a gradual and controlled profile. The quantity of the substance released is proportional to the initial content of ARZ, with a maximum observed for ARZ-Hap-3 (~900 mg/L). This mechanism, based on slow diffusion, confirms the potential of these materials for sustained release of active ingredients. Furthermore, a molecular docking analysis was conducted to explore potential interactions between ARZ and biological targets associated with the pathogens studied. The results of the study indicated a high binding affinity of ARZ with certain enzymes that are essential for bacterial and fungal survival. This finding corroborates the experimental observations made in the study, thereby providing a scientific rationale for the observed effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.